Jeff Vierstra, a 41-year-old scientist and skier, is participating in an experimental treatment aimed at preventing Amyotrophic Lateral Sclerosis (ALS), a disease that has claimed the lives of his mother and two sisters. Vierstra, who carries a mutation of the FUS gene linked to ALS, experienced emotional turmoil regarding his family history of the disease. His sisters developed ALS symptoms and took part in a clinical trial at Columbia University’s Eleanor and Lou Gehrig ALS Center, where Vierstra was also offered the same treatment. For the past three years, he has received spinal infusions targeting the mutated gene. While his sisters ultimately succumbed to ALS, Vierstra has not yet developed the disease and has shown improvement in his muscle testing results. Dr. Neil Shneider, who leads the trial, expresses optimism that such research may help transform ALS into a manageable condition.
Why It Matters
ALS, also known as Lou Gehrig’s disease, affects approximately 35,000 people in the United States, leading to the progressive degeneration of motor neurons. Genetic forms of ALS account for 10-15% of cases, with familial occurrences affecting multiple generations. Current research, including the trial at Columbia University, aims to develop individualized gene-based therapies for both familial and non-familial ALS forms. The outcomes of these studies could have significant implications for understanding and treating various neurodegenerative diseases, potentially improving the quality of life for many affected individuals.
Want More Context? 🔎
